Can We Repair Myelin in Multiple Sclerosis? Results from the CCMR-Two Trial
Om avsnittet
Can damaged myelin be repaired in people living with multiple sclerosis? Results from the CCMR-Two clinical trial presented at ECTRIMS 2025 offered promising new evidence for remyelination using a combination of metformin and clemastine.
Straight from his late-breaking presentation in Barcelona, trial lead Dr. Nick Cunniffe of the University of Cambridge joins host Brett Drummond to explain what the results mean, what researchers are learning about the biology of myelin repair, and the next steps towards developing future remyelination therapies for MS.
This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.
Fler avsnitt
Visa alla avsnitt av The ECTRIMS PodcastThe ECTRIMS Podcast med The European Committee for Treatment and Research in Multiple Sclerosis finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.